Alpha-one antitrypsin (AAT) deficiency is a genetic disease that results in both lung disease and potentially liver failure in affected patients. In un-affected people AAT is produced in the liver and secreted to act as an anti-protease (primarily counteracting the effects of neutrophil elastase) in the lung. On-going human clinical trials have focused on intra-muscular delivery of adeno-associated virus (AAV1) to patients. The goal of delivery to the muscle is to have the myocytes serve as bio-factories to produce normal AAT protein and secrete it into the blood where it can exert its normal function in the lung. In the last Phase II trial patients in the highest dose cohort were given 100 intra-muscular (IM) injections with serum AAT leve...
Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials f...
Gene therapy offers a promise for treating inherited muscle disorders. The advantages of recombinant...
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to...
Alpha-one antitrypsin (AAT) deficiency is a genetic disease affecting the lungs due to inadequate an...
Phase 1 and phase 2 gene therapy trials using intramuscular (IM) administration of a recombinant ade...
Alpha-1 antitrypsin (AAT) deficiency is a common monogenic disorder resulting in emphysema, which is...
Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for human gene transfer. We performe...
Recombinant adeno-associated virus (rAAV) vectors offer promise for the gene therapy of α(1)-antitry...
With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zol...
Pompe disease is a severe disorder caused by loss of acid α-glucosidase (GAA), leading to glycogen a...
Recombinant adeno-associated viral (rAAV) vectors have been widely used in pulmonary gene therapy re...
Recombinant adeno-associated virus (rAAV) vectors offer promise for gene therapy of alpha-1 antitryp...
The liver is a major off-target organ in gene therapy approaches for cardiac and musculoskeletal dis...
Alpha-1 antitrypsin deficiency is a monogenic disorder resulting in emphysema due principally to the...
INTRODUCTION: As a common monogenic disease, alpha-1 antitrypsin (AAT) deficiency has undergone thor...
Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials f...
Gene therapy offers a promise for treating inherited muscle disorders. The advantages of recombinant...
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to...
Alpha-one antitrypsin (AAT) deficiency is a genetic disease affecting the lungs due to inadequate an...
Phase 1 and phase 2 gene therapy trials using intramuscular (IM) administration of a recombinant ade...
Alpha-1 antitrypsin (AAT) deficiency is a common monogenic disorder resulting in emphysema, which is...
Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for human gene transfer. We performe...
Recombinant adeno-associated virus (rAAV) vectors offer promise for the gene therapy of α(1)-antitry...
With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zol...
Pompe disease is a severe disorder caused by loss of acid α-glucosidase (GAA), leading to glycogen a...
Recombinant adeno-associated viral (rAAV) vectors have been widely used in pulmonary gene therapy re...
Recombinant adeno-associated virus (rAAV) vectors offer promise for gene therapy of alpha-1 antitryp...
The liver is a major off-target organ in gene therapy approaches for cardiac and musculoskeletal dis...
Alpha-1 antitrypsin deficiency is a monogenic disorder resulting in emphysema due principally to the...
INTRODUCTION: As a common monogenic disease, alpha-1 antitrypsin (AAT) deficiency has undergone thor...
Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials f...
Gene therapy offers a promise for treating inherited muscle disorders. The advantages of recombinant...
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to...